New research reveals that individuals who stop using popular GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass much more quickly than those who halt traditional lifestyle programs.
Published data in a prominent medical journal shows that while overweight people can lose substantial amounts of their body weight while on the medication, the weight returns at an average rate of nearly a kilo each month upon discontinuation.
"People purchasing such drugs need to be informed of the risk of fast rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
Such speed of regain means a return to original mass within about a year and a half.
Weighing Approaches
The study, which examined dozens of trials involving thousands of patients, contrasted the results of GLP-1 agonists with conventional dieting.
The team point out that people who lose weight through dieting typically see a slower weight regain—around 100 grams monthly—after stopping.
The Reason for the Quick Rebound
Nutrition scientists propose the mechanism of the drugs is key to understanding the accelerated rebound.
These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of the hormone levels far above than the body's typical production may cause the system to generate a reduced amount of its own natural GLP-1, and could reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication results in hunger is no longer kept in check, making binge eating a significant risk."
An Ongoing Issue?
Health authorities advise the jabs for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians contend that, considering the high risk of weight regain, the treatment should be considered ongoing.
This perspective is echoed by pharmaceutical companies, who note that the findings "highlight the persistent nature of obesity," comparing it to managing conditions like high blood pressure.
Patient Experiences
Individuals who have stopped the medication explain a sudden return of cravings.
"I experienced a trigger that goes on and you become starving," recalled a patient.
The struggle is exacerbated if users have not adopted lasting dietary or behavioural modifications during therapy.
Significant Use
Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Use is greater among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
Ultimately, clinicians caution that while the jabs are potent tools for weight loss, they are not a permanent fix and long-term success hinges on combined behavioural support.
